PharmacoEconomics

, Volume 16, Issue 5, pp 459–472 | Cite as

Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care

Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia
  • Pierre-Yves Cremieux
  • Stan N. Finkelstein
  • Ernst R. Berndt
  • Jeffrey Crawford
  • Mitchell B. Slavin
Original Research Article

Abstract

Objective: To measure the cost effectiveness of a supportive care intervention when the no-treatment option is unrealistic in an analysis of recombinant human erythropoietin (epoetin) treatment for anaemic patients with cancer undergoing chemotherapy. Further, to assess whether quality-adjusted life-years (QALYs) can provide the basis for an appropriate measure of the value of supportive care interventions.

Design: A modelling study drawing cost and effectiveness assumptions from a literature review and from 3 US clinical trials involving more than 4500 patients with cancerwhowere treatedwith chemotherapy, radiotherapy, epoetin and blood transfusions as needed under standard care for patients with cancer.

Main outcome measures and results: When compared with transfusions, epoetin is cost effective under varying assumptions, whether effectiveness is measured by haemoglobin level or quality of life. Specifically, under a base-case scenario, the effectiveness resulting from $US1 spent on standard care can be achieved with only $US0.81 of epoetin care. Due in part to the health-state dependence of the significance patients attach to incremental changes in their responses on the linear analogue scale, cost per QALY results are ambiguous in this supportive care context.

Conclusions: Under a broad range of plausible assumptions, epoetin can be used cost effectively in the treatment of anaemic patients with cancer. Further, QALYs have limited applicability here because, as a short term supportive treatment, epoetin enhances the quality but not the length of life. Future research would benefit from the establishment of consistent values for quality-of-life changes across patients and health status, and the extension of the QALY framework to supportive care.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abels R. Erythropoietin for anemia in cancer patients. Eur J Cancer 1993; 29A: S2–8CrossRefGoogle Scholar
  2. 2.
    Case D, Bukowski R, Carey R, et al. Recombinant-human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85 (10): 801–6PubMedCrossRefGoogle Scholar
  3. 3.
    Glaspy J, Bukowski R, Steinberg D, et al. The impact of therapy with epoetin alfa on clinical outcomes during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218–34PubMedGoogle Scholar
  4. 4.
    Demetri G, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16 (10): 3412–25PubMedGoogle Scholar
  5. 5.
    Sheffield R, Sullivan S, Saltiel E, et al. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997; 31: 15–22PubMedGoogle Scholar
  6. 6.
    Finkelstein S, Huber S, Greenberg P. Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997; 31: 1094PubMedGoogle Scholar
  7. 7.
    Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998; 78 (6): 781–7PubMedCrossRefGoogle Scholar
  8. 8.
    Ortega A, Dranitsaris G, Puodziunas ALV. What are cancer patients willing to pay for prophylactic epoetin alfa. Cancer 1998; 83 (12): 2588–96PubMedCrossRefGoogle Scholar
  9. 9.
    Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996Google Scholar
  10. 10.
    Padilla GV, Grant MM, Ferrell, et al. QL and cancer. In: Spilker B, editor. Quality-of-life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 301–8Google Scholar
  11. 11.
    McCormack H, Horne D, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988; 18: 1007–19PubMedCrossRefGoogle Scholar
  12. 12.
    Shulman K, Linas B. Pharmacoeconomics: state of the art in 1997. Annu Rev Public Health 1997; 18: 529–48CrossRefGoogle Scholar
  13. 13.
    Yellen S, Cella D, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63–74PubMedCrossRefGoogle Scholar
  14. 14.
    Cantor S, Hudson D, Lichtiger B, et al. The costs of blood transfusion: a process flow analysis. J Clin Oncol 1998; 16: 2364–70PubMedGoogle Scholar
  15. 15.
    Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995; 35: 427–30PubMedCrossRefGoogle Scholar
  16. 16.
    Health Care Financing Administration (HCFA). Part B extract summary system. Baltimore (MD): HCFA, 1997Google Scholar
  17. 17.
    American Cancer Society. Estimated new cancer cases [on line]. Available from: URL: http://www.cancer.org/statistics/cff98-/graphicaldata.html. [accessed 1999 Aug 11]Google Scholar
  18. 18.
    Mehrez A, Gafni A. Healthy-year equivalent versus quality-adjusted life years: in pursuit of progress. Med Decis Making 1993; 13 (4): 287–92PubMedCrossRefGoogle Scholar
  19. 19.
    Nord E. The validity of a visual analogue scale in determining social utility weights for health states. Int J Health Plann Manage 1991; 6: 234–42PubMedCrossRefGoogle Scholar
  20. 20.
    Leplège A, Hunt S. The problem of QL in medicine. JAMA 1997; 278: 47–50PubMedCrossRefGoogle Scholar
  21. 21.
    Crown WH, Obenchain RL, Englehart L, et al. The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. Stat Med 1998; 17: 1943–58PubMedCrossRefGoogle Scholar
  22. 22.
    Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16: 33–64PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Pierre-Yves Cremieux
    • 1
    • 2
  • Stan N. Finkelstein
    • 3
  • Ernst R. Berndt
    • 3
  • Jeffrey Crawford
    • 4
  • Mitchell B. Slavin
    • 5
  1. 1.Analysis Group/EconomicsCambridgeUSA
  2. 2.Department of EconomicsUniversity of QuebecMontrealCanada
  3. 3.Sloan School of ManagementMassachusetts Institute of TechnologyCambridgeUSA
  4. 4.Duke University Medical CenterDurhamUSA
  5. 5.Clinical Affairs, Ortho Biotech Inc.RaritanUSA

Personalised recommendations